<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503854</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0936</org_study_id>
    <nct_id>NCT00503854</nct_id>
  </id_info>
  <brief_title>Fatigue and Symptom Burden in Febrile Neutropenia</brief_title>
  <official_title>Fatigue and Symptom Burden in Febrile Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        -  To determine whether fatigue improves as patients are treated for febrile neutropenia
           (Day #1, Day #2 and Day #6).

      Secondary Objectives:

        -  To identify clinical factors associated in cancer patients with low risk for outpatient
           treatment of febrile neutropenia on either outpatient febrile neutropenia treatment
           pathway presenting with moderate to severe fatigue. Moderate fatigue is defined as a
           score of 4 through 6 on the Brief Fatigue Inventory and severe fatigue is defined as a
           score of 7 through 10 on the Brief Fatigue Inventory.

        -  To describe demographic information in cancer patients with low risk for outpatient
           treatment of febrile neutropenia and fatigue while enrolled in either of two outpatient
           febrile neutropenia treatment pathways.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2007</start_date>
  <completion_date type="Actual">April 5, 2018</completion_date>
  <primary_completion_date type="Actual">April 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in mean fatigue level from study day 1 to day 6</measure>
    <time_frame>6 Days (Baseline to Day 6)</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Fatigue and Fever Assessment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaires taking about 15 to 30 minutes total.</description>
    <arm_group_label>Fatigue and Fever Assessment</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with solid tumors at low risk for outpatient treatment of febrile neutropenia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cancer patients with solid tumors at low risk for outpatient treatment of febrile
             neutropenia evaluated in the EC and enrolled in outpatient febrile neutropenia
             pathways (pathway 1 or 2). Low risk is defined as hemodynamically stable solid tumor
             patients that do not have pneumonia or are on steroids. Febrile neutropenia is marked
             by a temperature greater than or equal to 38.3 degrees Celsius and an absolute
             neutrophil count (ANC) less than or equal to 1000 within 24 hours.

          2. Patients must be able to speak, read and write in English.

          3. Patients must be able to complete the required survey tools independently.

          4. Patients must report a moderate to severe fatigue level to question # 3 of the BFI( 4
             or greater on a 0-10 scale) on EC admission day.

          5. Pregnant women if they meet eligibility criteria of the NF pathway and are able to
             take the oral/IV antibiotic prescribed by th pathway.

          6. Patient must be greater or equal to 18 years of age.

        Exclusion Criteria:

        1) Patients will be excluded from the study if they are not on the neutropenic pathway at
        the time of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Escalante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Febrile Neutropenia</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Symptom Burden</keyword>
  <keyword>Questionnaire</keyword>
  <keyword>Survey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

